ChemoCentryx, Inc. (CCXI) EPS Estimated At $-0.11; Sabre Industries (SABR) Has 1.76 Sentiment




July 30, 2018 – By Vernon Prom

Sabre Corporation (NASDAQ:SABR) Logo

Sabre Industries Inc (SABR) investors sentiment increased to 1.76 in Q1 2018. It’s up 0.29, from 1.47 in 2017Q4. The ratio is positive, as 167 funds increased or started new positions, while 95 reduced and sold their stakes in Sabre Industries Inc. The funds in our database reported: 289.05 million shares, down from 294.44 million shares in 2017Q4. Also, the number of funds holding Sabre Industries Inc in top ten positions increased from 3 to 5 for an increase of 2. Sold All: 19 Reduced: 76 Increased: 105 New Position: 62.

Analysts expect ChemoCentryx, Inc. (NASDAQ:CCXI) to report $-0.11 EPS on August, 14.They anticipate $0.08 EPS change or 42.11% from last quarter’s $-0.19 EPS. After having $-0.19 EPS previously, ChemoCentryx, Inc.’s analysts see -42.11% EPS growth. The stock decreased 0.53% or $0.06 during the last trading session, reaching $11.31. About 74,188 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since July 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx

Silver Lake Group L.L.C. holds 13.27% of its portfolio in Sabre Corporation for 22.47 million shares. Tpg Group Holdings (Sbs) Advisors Inc. owns 36.99 million shares or 11.95% of their US portfolio. Moreover, Praesidium Investment Management Company Llc has 5.11% invested in the company for 2.90 million shares. The New York-based Md Sass Investors Services Inc has invested 4.17% in the stock. Burgundy Asset Management Ltd., a Ontario – Canada-based fund reported 18.12 million shares.

Sabre Corporation, through its subsidiary, Sabre Holdings Corporation, provides technology solutions to the travel and tourism industry worldwide. The company has market cap of $7.12 billion. It operates through two divisions, Travel Network, and Airline and Hospitality Solutions. It has a 29.68 P/E ratio. The Travel Network segment operates as a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments.

Analysts await Sabre Corporation (NASDAQ:SABR) to report earnings on July, 31 before the open. They expect $0.31 earnings per share, down 3.13% or $0.01 from last year’s $0.32 per share. SABR’s profit will be $85.18M for 20.90 P/E if the $0.31 EPS becomes a reality. After $0.39 actual earnings per share reported by Sabre Corporation for the previous quarter, Wall Street now forecasts -20.51% negative EPS growth.

The stock increased 0.39% or $0.1 during the last trading session, reaching $25.91. About 1.03 million shares traded. Sabre Corporation (SABR) has risen 4.27% since July 30, 2017 and is uptrending. It has underperformed by 8.30% the S&P500. Some Historical SABR News: 24/05/2018 – Ketchum Wins Seven EMEA SABRE Awards; 23/05/2018 – S&PGR: Expect Sabre Will Maintain Leadership Position in Global Travel Distribution Systems Business and Grow Airlines Solution and Hospitality Business; 22/03/2018 – SABRE INSURANCE GROUP PLC SBRE.L – FY COMBINED OPERATING RATIO 68.5% VS 69.3%; 01/05/2018 – Alaska Airlines Migrates Virgin Amer Into Their Sabre Passenger Services System; 22/03/2018 – SABRE INSURANCE GROUP PLC SBRE.L – FY SOLVENCY COVERAGE RATIO 160% VS 128%; 14/05/2018 – Laurion Capital Buys New 1% Position in Sabre; 30/05/2018 – Sabre Insurance Cofounder, Investor Sell 18% Stake for GBP112.8 Mln; 23/05/2018 – S&P REVISES SABRE HOLDINGS CORP. TO RATING ‘BB’ FROM ‘BB-‘; 23/05/2018 – S&P REVISES SABRE CORP. TO RATING ‘BB’ FROM ‘BB-‘; 22/05/2018 – LATAM Airlines Group now fully powered by Sabre’s passenger services system

Another recent and important Sabre Corporation (NASDAQ:SABR) news was published by Seekingalpha.com which published an article titled: “Aerolineas Argentinas renews partnership with Sabre” on July 12, 2018.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It is negative, as 10 investors sold ChemoCentryx, Inc. shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. National Bank Of Ny Mellon Corporation accumulated 106,620 shares. Moreover, Arrowstreet Partnership has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Bb&T Secs Ltd Co holds 83,500 shares. Ameritas Inv Prns reported 2,120 shares. Fernwood Invest Ltd Liability Company invested 0.08% in ChemoCentryx, Inc. (NASDAQ:CCXI). The Pennsylvania-based Pnc Fin Grp Inc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Renaissance Lc reported 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Fny Managed Accounts Lc stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 11,574 are held by Trexquant Limited Partnership. Barclays Public Limited Company stated it has 13,066 shares or 0% of all its holdings. Clarivest Asset Mngmt stated it has 79,000 shares or 0.02% of all its holdings. Schwab Charles Inv Inc reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Royal Natl Bank Of Canada invested in 0% or 3 shares. California State Teachers Retirement Sys accumulated 0% or 38,188 shares. The New York-based Jane Street Grp Ltd Llc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

Since May 1, 2018, it had 0 insider purchases, and 12 insider sales for $7.89 million activity. Schall Thomas J. sold $2.36M worth of stock or 200,000 shares. KANAYA SUSAN M sold $752,925 worth of stock. $590,637 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) was sold by Cappel Markus J..

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $555.89 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since March 13, 2018 according to SRatingsIntel. The rating was maintained by JP Morgan on Tuesday, March 13 with “Overweight”.

Sabre Corporation (NASDAQ:SABR) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *